RECRUITING

Change in Omega 3 Index in Healthy Adults with OmeGo or a Standard Omega-3 Oil Supplement

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Omega-3 index is used as a proxy for an adequate intake of fish unsaturated fats in the diet. However, omega-3 supplements have not consistently shown the health benefits of eating fresh fish. This study will assess the change in omega-3 index and impact on markers of cardiometabolic health with two different supplements: a whole, unprocessed salmon oil and a standard, processed, concentrated oemga-3 oil. The markers to be studies included impact on inflammation and oxidative stress, cholesterol and markers of risk of diabetes. Change in sleep metrics will also be assessed.

Official Title

A Randomized Controlled Clinical Trial Assessing the Impact of 14-week Natural Salmon Oil Supplementation (CARDIO®) on the Omega-3 Index Response and Cardiometabolic and Inflammatory Biomarkers in Healthy, Non-Pregnant Adults

Quick Facts

Study Start:2025-02-18
Study Completion:2025-10-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06802068

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:40 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Healthy, non-pregnant adults; 40-80 years of age; stable body weight prior 3 months
  1. * Fish or seafood allergies; Pregnant; already consuming fish oil supplementation; malabsorption states; malignancy in remission for less than 12 months; diabetic

Contacts and Locations

Study Contact

Crawford Currie, MBBS
CONTACT
1-650-206-8006
cc@hofsethbiocare.no
Christian Bjerknes, MD
CONTACT
1-650-206-8006
chbj@hofsethbiocare.no

Principal Investigator

Crawford Currie, MBBS
PRINCIPAL_INVESTIGATOR
HBC

Study Locations (Sites)

Alethios
Menlo Park, California, 94025
United States
Alethios, Inc.
San Francisco, California, 94109
United States

Collaborators and Investigators

Sponsor: Hofseth Biocare ASA

  • Crawford Currie, MBBS, PRINCIPAL_INVESTIGATOR, HBC

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02-18
Study Completion Date2025-10-01

Study Record Updates

Study Start Date2025-02-18
Study Completion Date2025-10-01

Terms related to this study

Keywords Provided by Researchers

  • Omega-3 index, salmon oil CARDIO, omega-3 oil

Additional Relevant MeSH Terms

  • Supplementation in Healthy Adults to Assess Impact on Omega 3 Index and Cardiometabolic Health